Doris Kraemer

TL;DR: A phase 2 hypothesis-generating trial to determine whether the addition of the multitargeted kinase inhibitor midostaurin to intensive chemotherapy followed by allogeneic hematopoietic cell transplantation and single-agent maintenance therapy of 12 months is feasible and favorably influences event-free survival (EFS) compared with historical controls.

TL;DR: Comorbidities have no impact on treatment success but do have a negative effect on OS, indicating that survival of patients with CML is determined more by comorbidity than by CML itself, and OS may be inappropriate as an outcome measure for specific CML treatments.

TL;DR: Age-adjusted analysis revealed improved survival after high-dose chemo/radiotherapy followed by allogeneic stem cell transplantation when performed in first complete remission, which should be recommended for eligible patients with CD4+CD56+ malignancy.

TL;DR: Describing genetic and clinical characteristics of acute myeloid leukemia (AML) patients according to age from an academic population-based registry revealed excellent coverage in patients < 70 years old and good coverage up to the age of 80, while regarding treatment, obesity and favorable risk were associated with an intensive treatment, whereas adverse risk, higher age, and comorbidity index > 0 were associatedWith non-intensive treatment or best supportive care.

TL;DR: On the basis of the acceptable toxicity profile and favorable outcome in the AMLSG 11–08 trial, a confirmatory randomized phase III trial with dasatinib in adults with CBF-AML is ongoing (ClinicalTrials.gov Identifier: NCT02013648).